GlassScriptPhysician profile
Laura Kimball Ravari
NPI 1861437543
$164,536.77
in general payments reported to CMS, 2019-2025
59 companies · $42K in 2025
The $42K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $4,374 · 2021: $3,603 · 2022: $57K · 2023: $23K · 2024: $18K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $8,078 · Honoraria: $4,400 · Travel and Lodging: $3,007 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,245.25 |
| Food and Beverage | $8,078.22 |
| Honoraria | $4,400.00 |
| Travel and Lodging | $3,006.78 |
| Education | $198.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $116,567.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $14,325.75 | 2019-2025 | |
| Abbvie INC. | $11,523.88 | 2019-2025 | |
| Corcept Therapeutics | $9,358.19 | 2019-2025 | Korlym |
| Medtronic, INC. | $1,950.58 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $1,337.28 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Amgen INC. | $1,041.33 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $659.05 | 2019-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $653.16 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $597.02 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $578.38 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $461.82 | 2019-2025 | Omnipod |
| Abbott Laboratories | $429.38 | 2019-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $371.91 | 2019-2024 | Xyosted |
| Recordati_rare_diseases_inc. | $359.99 | 2021-2025 | Isturisa, Signifor Lar |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $295.81 | 2021-2022 | |
| Medtronic Minimed, INC. | $294.19 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $266.66 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $264.71 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.87 | 2019-2025 | Jardiance, Tradjenta |
| Currax Pharmaceuticals LLC | $243.19 | 2019-2023 | Contrave |
| Merck Sharp & Dohme LLC | $217.29 | 2019-2022 | |
| Shire North American Group INC | $196.35 | 2019 | |
| Radius Health, INC. | $167.95 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $163.68 | 2022-2023 | Tepezza |
| Pfizer INC. | $155.96 | 2019-2025 | |
| Ibsa Pharma INC. | $147.20 | 2020-2025 | Tirosint, Licart, Tirosint |
| Lundbeck LLC | $125.00 | 2025 | Vyepti |
| Kowa Pharmaceuticals America, INC. | $116.49 | 2019-2023 | Livalo, Seglentis |
| Acella Pharmaceuticals, LLC | $106.83 | 2022-2025 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $106.13 | 2019-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $97.86 | 2023-2025 | Yorvipath |
| Nevro Corp. | $95.01 | 2022-2023 | Senza |
| Janssen Pharmaceuticals, INC | $89.51 | 2019-2020 | |
| Chiasma, INC. | $84.99 | 2021 | |
| Grt US Holding, INC. | $78.82 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $59.96 | 2025 | Evkeeza |
| Eusa Pharma (US) LLC | $58.38 | 2022 | |
| Kyowa Kirin, INC. | $54.65 | 2023-2024 | Crysvita |
| Sequel Med Tech, LLC | $54.58 | 2025 | Twiist |
| Averitas Pharma INC. | $51.30 | 2024 | Qutenza |
| Neurocrine Biosciences, INC. | $50.37 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $49.13 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $41.58 | 2019 | |
| Amryt Pharma Holdings LTD | $39.96 | 2022-2023 | Mycapssa |
| Clarus Therapeutics INC. | $31.72 | 2021 | |
| Madrigal Pharmaceuticals | $31.63 | 2025 | Rezdiffra |
| Cequr Corporation | $30.10 | 2025 | Cequr Simplicity |
| Halozyme INC | $24.71 | 2023 | |
| Boston Scientific Corporation | $20.69 | 2019 | |
| Beta Bionics, INC. | $20.17 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Chiesi USA, INC. | $19.16 | 2025 | Mycapssa |
| Takeda Pharmaceuticals U.S.A., INC. | $18.94 | 2020 | |
| Opko Pharmaceuticals, LLC | $17.48 | 2023 | Rayaldee |
| Rhythm Pharmaceuticals, INC. | $17.01 | 2025 | Imcivree |
| Vifor Pharma, INC. | $16.92 | 2021 | |
| Melinta Therapeutics, LLC | $13.93 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Glaxosmithkline, LLC. | $13.57 | 2019 | |
| Zealand Pharma US, INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Kimball Ravari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.